Nivolumab Global Market Report 2024

The global nivolumab market has grown rapidly in recent years. It will grow from $1.47 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to immunotherapy advancements, increased incidence of cancer, clinical trial success, regulatory approvals.

The global nivolumab market is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to personalized medicine, emerging indications, global access to cancer care, advancements in combination therapies. Major trends in the forecast period include biomarker-driven treatment, neoantigen vaccines, enhanced immunotherapy regimens, long-term follow-up studies.

The growth of the nivolumab market is set to be significantly propelled by the increasing prevalence of cancer. Cancer encompasses a broad spectrum of diseases that can manifest in nearly any organ or tissue within the body. It is characterized by the uncontrolled proliferation of abnormal cells, which can breach their usual boundaries and have the potential to metastasize to other organs or infiltrate neighboring tissues. Nivolumab, a key player in cancer treatment, functions by preventing cancer cells from suppressing the immune system, thereby enabling the immune system to identify, target, and eliminate these malignant cells. As an illustrative instance, the American Cancer Society Inc., a non-profit health organization based in the United States, predicts that in 2023, there will be a staggering 1.9 million new cancer cases diagnosed in the U.S., marking an increase compared to the over 1.8 million cases identified in 2020. Consequently, the burgeoning prevalence of cancer serves as a robust driving force behind the expansion of the nivolumab market.

The increasing incidence of non-small cell lung cancer (NSCLC) is poised to be a prominent driver for the Nivolumab market's growth in the foreseeable future. NSCLC, a prevalent form of lung cancer originating in the epithelial cells of the lungs, is a major area of focus for Nivolumab. The drug has garnered approval for the treatment of advanced non-small cell lung cancer (NSCLC) owing to its proven efficacy in addressing this specific condition. Notably, data from the American Society of Clinical Oncology reveals that an estimated 238,340 individuals (comprising 117,550 men and 120,790 women) are anticipated to receive a lung cancer diagnosis in the United States in March 2023. Among these cases, NSCLC is the predominant subtype, representing approximately 81% of all lung cancer diagnoses. Consequently, the increased incidence of non-small cell lung cancer (NSCLC) stands as a formidable growth driver for the Nivolumab market.

The primary hurdle constraining market growth during the forecast period is the potential immune-related adverse events (IR-AEs) associated with Nivolumab usage. Nivolumab, known as an immune checkpoint inhibitor, has emerged as an innovative therapeutic option for cancer treatment. However, it is accompanied by several IR-AEs, including thyroid complications, colitis, pneumonitis, and, though rare, conditions such as type 1 diabetes, Guillain-Barré syndrome, and myasthenia gravis. The elevated incidence of IR-AEs linked to Nivolumab administration raises concerns regarding their potential increase as Nivolumab usage expands. For instance, in July 2021, the US-based pharmaceutical company Bristol-Myers Squibb made the challenging decision to voluntarily withdraw Opdivo (nivolumab) from the U.S. market as a monotherapy for individuals with hepatocellular carcinoma (HCC) who had previously received sorafenib treatment. Thus, the limiting factor influencing the Nivolumab market's growth is the possible immune-related adverse events associated with its utilization.

Prominent companies operating within the Nivolumab market are placing a significant emphasis on the development of innovative drugs aimed at enhancing patient care and sustaining their market positions. The creation of novel drugs holds the potential to improve treatment outcomes for patients grappling with various medical conditions. As an illustration, in May 2022, Bristol-Myers Squibb Co., a US-based pharmaceutical company primarily dedicated to therapeutic endeavors encompassing cancer, cardiovascular health, immunology, and fibrotic conditions, disclosed the FDA's approval of two Nivolumab-based regimens. These regimens included Nivolumab in combination with fluoropyrimidine and platinum-containing chemotherapy and Nivolumab paired with Yervoy (ipilimumab), for the first-line treatment of adult patients dealing with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status.

In November 2022, Lyvgen Biopharma Co. Ltd., a China-based biotechnology firm specializing in cancer treatment, entered into a collaborative partnership with Bristol-Myers Squibb Co. The collaboration's focal point is the assessment of LVGN7409 in conjunction with Nivolumab, targeting patients with non-small cell lung cancer. This combination therapy concurrently addresses the co-stimulatory checkpoint CD40 and the co-inhibitory checkpoint PD-1. This multifaceted approach is envisioned to enhance the effectiveness of immunotherapy for patients confronting diseases that exhibit resistance or refractoriness. Bristol-Myers Squibb Co. is a US-based pharmaceutical company with a primary focus on therapeutic domains spanning cancer, cardiovascular health, immunology, and fibrotic disorders, inclusive of pioneering developments in Nivolumab.

Major players in the nivolumab market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Nippon Kayaku Co. Ltd., Luye Pharma AG, Genentech Inc., Taiho Pharmaceutical Co. Ltd., SymBio Pharmaceuticals Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc.

North America was the largest region in the nivolumab market in 2023. The regions covered in nivolumab report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the nivolumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nivolumab is available in two main formulations such as an injection of 4 mL and an injection of 10 mL. The 40 mg/4 mL (10 mg/mL) solution of nivolumab is provided in single-use vials. This formulation is utilized in the treatment of melanoma, non-small cell lung cancer (NSCLC), and Hodgkin lymphoma. It is administered via intravenous and other routes for the treatment of conditions such as melanoma, NSCLC, malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and other cancer types. Nivolumab is used in clinical settings, hospitals, and other healthcare facilities for cancer treatment.

This report provides nivolumab market statistics, including nivolumab industry global market size, regional shares, competitors with a nivolumab market share, detailed nivolumab market segments, market trends and opportunities and any further data you may need to thrive in the nivolumab industry. This nivolumab market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nivolumab market consists of sales of opdivo, nivolumab injection, generic Nivolumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.